论文部分内容阅读
目的观察孟鲁司特钠(顺尔宁)辅助治疗小儿肺炎支原体肺炎的临床疗效。方法选取我院自2009年5月～2011年8月收治的肺炎支原体肺炎患儿82例随机分为观察组(孟鲁司特钠辅助治疗组)42例和对照组(常规治疗组)40例,连续治疗2周后比较两组患儿的临床疗效。结果两组患儿发热消失时间无明显差异(P>0.05),但咳嗽、咯痰及喘息消失时间均有统计学差异(P<0.05)。两组患儿治疗过程中均未见明显不良反应。结论孟鲁司特钠(顺尔宁)辅助治疗小儿肺炎支原体肺炎可以缓解咳嗽等临床症状、缩短治疗周期,且安全性较高,值得推广应用。
Objective To observe the clinical efficacy of Montelukast (Salbutamol) adjuvant treatment of children with Mycoplasma pneumoniae pneumonia. Methods Eighty-two children with mycoplasma pneumoniae pneumonia admitted in our hospital from May 2009 to August 2011 were randomly divided into observation group (montelukast sodium adjuvant treatment group) and control group (n = 40) After two weeks of continuous treatment, the clinical efficacy of the two groups was compared. Results There was no significant difference in the disappearance of fever between the two groups (P> 0.05), but there were significant differences in cough, expectoration and wheezing (P <0.05). Two groups of children with no significant adverse reactions during the treatment. Conclusion Montelukast sodium (Salbutamol) adjuvant treatment of children with Mycoplasma pneumoniae pneumonia can relieve cough and other clinical symptoms, shorten the treatment cycle, and high safety, it is worth promoting the application.